32. (Amended) The method of Claim 29 in which the receptor or antigen is CR1, CR2, CR3, CR4, CD16, CD32, CD64, or CD89.

33. (Amended) The method of Claim 25 or 26, wherein at least one of the anti-C3b(i) antibodies is a monoclonal antibody.

34. (Amended) The method of Claim 25 or 26 further comprising administering to the animal IgG enriched plasma.

35. (Amended) The method of Claim 25 or 26 further comprising administering to the animal IgM enriched plasma.

36. (Amended) The method Claim 25 or 26 further comprising administering to the animal one or more complement components.

37. (Amended) The method of Claim 26 further comprising administering to the animal one or more nucleic acid sequences encoding one or more complement components.

38. (Amended) The method of Claim 25 in which at least one of the anti-C3b(i) antibodies is conjugated to a therapeutic agent.

43. (Amended) The method of Claim 25 in which at least one of the anti-C3b(i) antibodies is conjugated to a detectable agent.

44. (Amended) The method of Claim 25 or 26 further comprising administering to the animal plasma.

45. (Amended) The method of Claim 25 or 26 in which the animal is a mammal.

46. (Amended) The method of Claim 25 or 26 in which the animal is a human.

Add new Claims 47-71, as follows:

22 ~~47.~~ (New) A method of treating cancer in an animal, said method comprising administering to said animal a therapeutically effective amount of an antibody immunospecific for C3b(i) covalently linked to IgM or IgG bound to cancer cells.

23 ~~48.~~ (New) A method of treating cancer in an animal, said method comprising administering to said animal a therapeutically effective amount of an antibody immunospecific for C3b(i) covalently linked to proteins or lipids on cancer cells.

24 ~~49.~~ (New) A method of treating cancer in an animal, said method comprising administering to said animal a therapeutically effective amount of an anti-C3b(i) antibody and an anti-CD20 antibody.

25 ~~50.~~ (New) The method of Claim 2 ~~23~~, wherein the cancer cell antigen is CD20, HER2 or PSMA.

26 ~~51.~~ (New) The method of Claim 24 ~~49~~, wherein the anti-C3b(i) antibody is a bispecific antibody which is immunospecific for C3b(i) and an effector cell receptor or antigen.

27 ~~52.~~ (New) The method of Claim 26 ~~51~~ in which the effector cell is a lymphocyte, monocyte, macrophage, dendritic cell, neutrophil, natural killer cell, or erythrocyte.

28 ~~53.~~ (New) The method of Claim 27 ~~52~~ in which the effector cell is an erythrocyte.

29 ~~54.~~ (New) The method of Claim 26 ~~51~~ in which the antigen is CR1, CR2, CR3, CR4, CD16, CD32, CD64, or CD89.

30 ~~55.~~ (New) The method of Claim 22 23 24 ~~47, 48 or 49~~, wherein the anti-C3b(i) antibody is a monoclonal antibody.

81

B5 Cont'd

31 ~~56.~~ (New) The method of Claim ~~55~~ 30 in which the monoclonal antibody is a human or humanized monoclonal antibody.

32 ~~57.~~ (New) The method of Claim ~~47~~ 22 or ~~48~~ 23 further comprising administering to the animal IgG or IgM enriched plasma.

33 ~~58.~~ (New) The method Claim ~~47~~ 22 or ~~48~~ 23 further comprising administering to the animal one or more complement components.

34 ~~59.~~ (New) The method of Claim ~~47~~ 23, ~~48~~ 23 or ~~49~~ 24 in which the anti-C3b(i) antibody is conjugated to a therapeutic agent.

35 ~~60.~~ (New) The method of Claim ~~57~~ 32 further comprising administering to the animal one or more complement components.

36 ~~61.~~ (New) The method of Claim ~~47~~ 22 or ~~48~~ 23 further comprising administering to the animal plasma.

37 ~~62.~~ (New) The method of Claim ~~47~~ 22, ~~48~~ 23 or ~~49~~ 24 in which the animal is a mammal.

38 ~~63.~~ (New) The method of Claim ~~62~~ 37 in which the mammal is a human.

39 ~~64.~~ (New) The method of Claim ~~25~~ 2, wherein at least one of the anti-C3b(i) antibodies is 3E7 produced by the hybridoma deposited with the ATCC as Accession No. PTA-4090.

40 ~~65.~~ (New) The method of Claim ~~47~~ 22, ~~48~~ 23 or ~~49~~ 24, wherein the anti-C3b(i) antibody is 3E7 produced by the hybridoma deposited with the ATCC as Accession No. PTA-4090.

41 ~~66.~~ (New) The method of Claim ~~49~~ 24, wherein the anti-CD20 antibody is rituximab.

42/67. (New) The method of Claim 24/~~49~~, wherein the anti-C3b(i) antibody is 3E7 produced by the hybridoma deposited with the ATCC as Accession No. PTA-4090 and the anti-CD20 antibody is rituximab.

43/68. (New) The method of Claim 24/~~49~~, wherein the anti-C3b(i) antibody is immunospecific for C3b(i) covalently linked to IgM or IgG bound to cancer cells.

44/69. (New) The method of Claim 24/~~49~~, wherein the anti-C3b(i) antibody is immunospecific for C3b(i) covalently linked to proteins or lipids in cancer cells.

45/70. (New) The method of Claim 22/~~47~~ or 23/~~48~~, further comprising administering to the animal one or more purified complement components.

46/71. (New) The method of claim 22/~~47~~ or 23/~~48~~, further comprising administering plasma to the animal.

REMARKS

The specification has been amended in order to insert a paragraph that states that the mouse hybridoma cell line that produces the anti-C3b(i) monoclonal antibody 3E7 described in the specification of the present application (see, *e.g.*, page 57, lines 6-16, page 62, lines 23-30, and page 69, lines 26-28 of the specification) was deposited with the American Type Culture Collection on February 21, 2002 and assigned Accession Number PTA-4090. Applicants are in the process of preparing and will file shortly in the United States Patent and Trademark Office a Statement of Applicant Regarding Permanence And Availability of Deposited Microorganisms, which attests to the deposit of the mouse hybridoma cell line Cbi-E7-E7-B8 under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, in compliance with the criteria set forth by 37 C.F.R. §§ 1.801-1.809 regarding the availability and permanence of deposits. Applicants respectfully assert that the amendment to the specification does not constitute new matter.

Claims 23-46 were pending in the present application. Applicants have amended Claims 26-29, 32-33, 35-39, and 43-46 and added new Claims 47-71 to clarify the subject